For HER2-positive breast cancer, as recommended by Chinese guidelines (24), AC followed by taxane, trastuzumab and pertuzumab (THP) is the preferred regimen of adjuvant therapy for patients with positive axillary lymph nodes. The gene discussed is ERBB2; the disease is breast cancer.